


KOREA DRUG DEVELOPMENT FUND

www.kddf.org/en

YOUR GATEWAY FOR INNOVATIVE
DRUG CANDIDATES IN SOUTH KOREA

KOREA DRUG DEVELOPMENT FUND

VERSION 4.0



Korea Drug Development Fund(KDDF) is a government agency funded by three government ministries. We aim to actively fund and provide the necessary support for drug development to academia and pharmaceutical industries.




USD 1.5 Bn

To grant 1,234 projects between 2021 and 2030

With a mission to foster Korea's biomedicine technologies and drug development programs, we aim to spend of USD 1.5Bn to grant 1,234 projects by 2030 so that innovations from academia and pharmaceutical companies can progress and flourish.

PROPERTY MANAGEMENT

Cumulative assets



APPROVED DRUG BY

FDA / EMA




MFDS




LICENSING DEALS

New licenses



Biodollars licensing deals




* Exchange currency: 1USD = 1,400kRW(2024.12)


PIPELINE OVERVIEW

TOTAL OF 423 PROJECTS

KDDF assets by stage, indication



KDDF assets by modality, indication



Co-development and licensing opportunities with KDDF's projects

KDDF is dedicated to advancing innovative drug development projects, spanning the entire process from early discovery to clinical stages. Our comprehensive support extends across academia, research institutions, biotechnology firms, and pharmaceutical companies, fostering collaboration and innovation. Beyond funding, KDDF provides strategic support for business development, facilitating out-licensing, co-development opportunities, and securing international investment, ensuring that promising projects achieve global success.

CPG Program

Co-development Partnering for Globalization



The CPG Program accelerates out-licensing and co-development by leveraging KDDF's extensive global network. Through collaboration with professional life science advisory firms, the program offers tailored consulting services, including deal strategy, asset valuation, and outreach marketing. Additionally, the program includes the Young BD Workshop, which enhances the expertise and networks of early-career business development professionals to strengthen their global partnership capabilities. This initiative empowers Korean pharmaceutical and biotech companies to achieve global partnerships and commercialization success.

Global Partnering Opportunities



KDDF actively connects Korean pharmaceutical and biotech companies with global pharmaceutical leaders and international investors. Signature events such as the Global Biotech Showcase and the Global Symposium for Co-development and Partnership serve as platforms for promising Korean companies to present their innovative projects for collaboration or venture funding.

In addition to these events, KDDF facilitates ongoing interactions, including regular updates on new projects and arranging direct meetings upon request from global partners, fostering seamless connections and opportunities.

Asset Valuation Services



KDDF provides in-depth asset valuation services to assess the potential value of drug development projects supported by KDDF funding. These analyses serve as strategic tools for out-licensing, M&A, and IPO preparation, offering critical insights that guide drug development and commercialization strategies.

Partner with KDDF



KDDF is committed to building lasting global partnerships. We continuously work to bridge the gap between Korean innovation and international collaboration through strategic events, consulting services, and robust networking opportunities.

To explore partnering opportunities with KDDF, contact us at kddf_bd@kddf.org.

PIPELINE DETAILS

As of December 2024

Oncology



Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Antibody								
ADC	Cancer	Doppel					-	Seoul National University ¹⁾
	Bladder cancer, Glioblastoma	FGFR3					AMB302	AimedBio Inc
	SCLC, GIST	c-Kit					NN3201	Novelty Nobility
	Rare cancer	DLL3					-	IntoCell ²⁾
	Metastatic breast cancer	HER3					-	IntoCell
	NSCLC	B7-H3					ITC-6146RO	IntoCell
	Solid Tumor	TROP2					TROP2-ADC	LigaChem Biosciences ³⁾
	Gastric cancer, Gastroesophageal junction edema cancer	CLDN18.2					AT-211	AbTis
	Solid tumor	CD171					APB-A001	APITBIO
	AML	CD33, GSPT1					TRX-214-1002	Therapex Corp.
	NSCLC	cMET					CKD-703	Chong Kun Dang pharmaceutical Corp.
BsAb	NHL, CLL	CD20, CD55					-	Korea University
	Solid Tumor	B7-H4, 4-1BB					ABL103	ABLBio
	NSCLC, Lung cancer, Colorectal cancer, Gastric cancer, TNBC, Ovarian cancer	PD-L1, LAG-3					ABL501	ABLBio
	NSCLC	c-MET, EGFR					CKD-702	Chong Kun Dang pharmaceutical Corp.
	Solid Tumor	PD-L1, SIRPa					-	PharmAbcine Inc
	Colerectal cancer	HLA-G, CD3					YBL-013	Y-Biologics
	TNBC	PD-L1, CD47					IOH-001	ImmuneOncia
	TNBC	Trop-2, NKp46, NKp30					-	Seoul National University

DRUG CLASS	INDICATION	TARGETS	KDDF FUNDING STAGE				PRODUCT CODE	COMPANY
			Discovery	Pre	Ph1	Ph2		
BsAb	Cancer	C4D, CD3					-	Seoul National University
	TNBC	CD47, CD73					-	AprilBio
	Solid Tumor	PD-L1, CD3					-	MustBio, Inc.
	Solid Tumor	PD-1, IL-2R					MB5029	MustBio, Inc.
	Solid Tumor	B7-H3/TGF-β					TN-01A	Theranotics
	Colorectal cancer	EGFR, 4-1BB					RACE-111	CT CELLS
	TNBC, NSCLC, PC	DDR1, TGF-β					-	POSTECH
	Solid Cancer	PD-L1/ ***					-	GI Innovation, Inc
mAb	Metastatic colorectal cancer	CCSP-2					-	Asan Medical Center
	Metastatic malignant melanoma	Oncokine-2					-	Korea University ⁴⁾
	Solid Tumor	TIGIT					-	HanAll Biopharma
	NSCLC	VISTA					PMC-309	PharmAbcine Inc
	Esophageal squamous cell carcinoma, TNBC, PTK7 expression cancer	PTK7					-	Yonsei University
	Lung cancer	NSN-001					-	NEX-I ⁵⁾
	Lung cancer	DDOST					-	Hanyang University
	Lung cancer, Colorectal cancer, Breast cancer	CD300c					CL7	CentricsBio Inc.
	Squamous cell carcinoma, Renal cell carcinoma, other solid tumor	PD-1					YBL-006	Y-Biologics
	Cancer cachexia	GFRAL					αGFRAL antagonistic mAb	TroyY
	Lung cancer	IGSF1					-	Wellmarkerbio ⁶⁾
	NSCLC	TMPRSS4					-	KRIBB
	Solid Tumor	CXCL16					-	Cellus
	Solid Tumor	TREM2					AMB018	AimedBio Inc
	NSCLC	CHI3L1					-	Senelix
	Solid Tumor	CNTN4					-	Genome&Company
	Solid cancer	APP					GENA-119	Genome&Company
	Solid Cancer	TCTP					BI0101	BOOSTIMMUNE

DRUG CLASS	INDICATION	TARGETS	KDDF FUNDING STAGE				PRODUCT CODE	COMPANY
			Discovery	Pre	Ph1	Ph2		
mAb	CLDN3hi solid cancer	CLDN3					abn501	ABION
	Cancer/mAb for ADC dev.	HGF					-	Seoul National University
	Melanoma	IL-36					-	DGIST
	Cancer	PSMA/CD137					-	AbClon Inc.
	Cancer	CD33					CTN008	Centenaire Biosciences
	Breast cancer, Gastric cancer	HER2					CTN001	Centenaire Biosciences
CGT & Nucleic acids								
Aptamer	Ovarian cancer	ALCAM					HC-102D	HiCELL Tech
	TNBC	Nucleolin					-	Interoligo
	Solid Tumor	CD25					CD25-ApDC	APTAMER Sciences
ASO	Liver cancer	let-7i-5p miRNA					NRT-YHD-001	NEORNAT
CAR_NK	Blood Cancer	CD5					-	KRIBB ⁷⁾
	Relapsed and Refractory Pancreatic cancer	Endoglin					-	KIST
	B-cell lymphoma	CD19					GCC2004	GC Cell
	NK & T Cell Lymphoma	CD5					GCC2005	GC Cell
CAR-T	Blood cancer	CAR-DEGRON-T					-	KRICT
	Solid Tumor	B7-H3, IL-12					-	Seoul National University
	Solid Tumor	IL-21					-	Seoul National University
	Blood tumor	CD40					-	TiCARos Inc
	MUC1 positive solid cancer	MUC1					-	TiCARos Inc
	B-cell Lymphoma	CD19					TC011	TiCARos Inc
	Non-small cell lymphoma	CD19					CRC01-01	Curocell Inc.
	Ovarian cancer	L1CAM					-	Cartexell Inc ⁸⁾
	NHL	CD19					AT101	AbClon Inc.
	B-cell Lymphoma	CD19					AT101	AbClon Inc.
	Glioblastoma	IL13Rα2					YYB-103	CellabMED
	Ovarian cancer	MSLN					-	CellenGene
	Solid tumor	HLA-G					IN-B014	Inno.N

DRUG CLASS	INDICATION	TARGETS	KDDF FUNDING STAGE				PRODUCT CODE	COMPANY
			Discovery	Pre	Ph1	Ph2		
CAR-T	Liver cancer	GPC3					EU307	Eutilex Co.
	Solid tumor (Ovarian Cancer)	EphA2, PD-L1					-	Vaxcell Bio
GT-Virus vec.	Ovarian cancer	EpCAM					oHSV-1	GenCellMed
	Pancreatic cancer, Liver cancer	TGFb1, HSP27					-	Yonsei University ⁹⁾
	Glioblastoma	TK & CD genes					ARTI 101	ArtiCure
	Hepatocellular Carcinoma	CR-P1					GR-G001	Curogen
	B-cell Lymphoma	NK cell					-	Denovo Biotherapeutics
mRNA	Solid Tumor	Tumor-specific T cells					VCN-100	Geninus
	TNBC	Neoantigen					-	Penta Medix
	NSCLC, SCLC	SOX2					-	Genexine
	Glioblastoma	Cytosine Deaminase					MSC11FCD	CELL & BRAIN Co., Ltd
Other-CT	Liver cancer	IL-15RF, HLA-G					TB-200	THERABEST
	Recurrent glioblastoma	-					CBT101	CHA Biotech
	Solid Tumor	IDO1					LEM-S403	Lemonex Inc.
RNA tx.	Bladder cancer, Head and neck cancer, Pancreatic cancer	mTOR, STAT3					CA102	Curigin ¹⁰⁾
	Ovarian cancer	c-Myc, BCL2					CA106-T	Curigin
	Pediatric brain tumor	BRAF					SVG301	SoVarGen Co., Ltd.
	Pancreatic cancer	KRAS/G12D					-	Exollence
	Solid Tumor	Neoantigen					NEOG-400	Neogen TC
TCR-T	EGFR L858R mutant lung cancer	pMHC					-	DAAN Biotherapeutics, Inc
Others-Bio.								
Other-B	Pancreatic cancer, Liver cancer	FAF1					-	ChungNam National University ¹¹⁾
	Solid Tumor	DCs					HynaDC	Yonsei University ¹²⁾
	Solid Tumor	FlaB, ClyA					-	CNCure biotech Inc.
	Colorectal cancer	-					-	CNCure biotech Inc.
	NHL	-					ProV-001	Progeneer
	HER2 low Gastric Cancer	HER2					KMD111	KMD Bio
	AML	aGC-loaded ECVN of AML					-	Seoul National University

Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Others-Synth.								
Other-S	Colorectal cancer, Breast cancer, Ovarian cancer, Pancreatic cancer	Cathepsin B					KMO022	Ewha Women's University
	Glioblastoma	TSPO					BS333	Seoul National University
	Malignant tumor	Macrophage					-	Seoul National University
MRcontrast agent	Diagnostic	-					ML-101	BL Melanis
rProtein								
Fusion Protein	Kidney cancer, Skin cancer	IL-2					-	GENUV
	Advanced or Metastatic Solid Tumor	CD80, IL-2					GI-101	GI Innovation, Inc
	Solid Tumor	CD73, IL-2					GI-108	GI Innovation, Inc
	Metastatic Melanoma	CTLA-4/PD-L1, IL-2R					GI-102	GI Innovation Inc.
	HER2+ tumor	IFN-β					GNP101	GenoPharm Bio
	Solid Tumor	FAP, IL-12					KNP-101	KANAPH Therapeutics ¹³⁾
	NSCLC, Melanoma	PD-L1, TIGIT					Cellem001	CELLmedy
PDC	Solid Tumor(EGFR overexpression)	EGFR					-	ProEn Therapeutics
Peptide	Pancreatic cancer, Lung cancer	KRAS mutant					NexaVac	NA Vaccine Institute
	GBM Glioblastoma, multifocal	-					-	NA Vaccine Institute
	Colorectal cancer	Phopholipid layer					AH-peptide	Sungkyunkwan University
	Lung cancer	-					-	Penta Medix
rProtein	Cancer	IL-21, PD-1					BNS001	BIOonSYSTEMS
	Pre-treated metastatic Pancreatic ductal adenocarcinoma	retinoid					RBP-albumin fusion protein	Senelix
	Renal cell carcinoma, Melanoma	IL-2					HM16390	Hanmi Pharm. Co., Ltd.
RPT								
RPT	Prostate cancer	PSMA					¹⁷⁷ Lu-FC705	FutureChem Co., Ltd.
	ccRCC	CAIX					CBT-001-839	Cbiomex
	Ovarian cancer	Folate receptor					-	ZTI Biosciences
	Prostate cancer	PSMA					PSMA-DGUL	CellBion Co., Ltd.

DRUG CLASS	INDICATION	TARGETS	KDDF FUNDING STAGE				PRODUCT CODE	COMPANY
			Discovery	Pre	Ph1	Ph2		
Small mole.								
Small mole.	Anaplastic Thyroid Cancer	SHMT2					-	KRICT
	Gastric cancer, Colon cancer	MAST3					-	KRICT
	Lung cancer	p53 or USE1					-	KRICT
	Solid Tumor	GLS1					TRG-0039	KRICT
	TNBC	TTK					-	KRICT
	Solid Cancer	FoxM1					-	KRICT
	Cancer	SIRT7					KRM-60801	KRICT
	Metastatic colorectal cancer	-					PPI	Chosun University
	Breast cancer (HR+ HER2-)	CDK7					C-16661	Cyrus Therapeutics
	Solid tumor	KRAS-SOS1 PPI					C2-558	Cyrus Therapeutics ¹⁴⁾
	Solid cancer (NF2 mutant, EGFR mutant, KRAS mutant)	TEAD1					DWP216	Daewoong Pharmaceutical
	Cancer	TPST2					-	GIST
	Chronic Myelogenous Leukemia	BTK (C481S)					SRT042	Medytox
	Breast cancer	HER2					BTS-A, B	B2SBio Inc. ¹⁵⁾
	Solid tumor	PKMYT1					-	Voronoï, Inc
	TNBC, CDK4/6 Inhibitor resistance solid cancer	Mps1					VRN081569	Voronoï, Inc ¹⁶⁾
	NSCLC(EGFR mutation)	EGFR					VRN110755	Voronoï, Inc
	Breast cancer, Colon cancer	HER2					VRN101099	Voronoï, Inc
	NSCLC	EGFR(C797S)					BBT-176	Bridge Biotherapeutics, Inc
	TNBC	HDAC6/8					-	Sookmyung Women's University
	Chronic Myelogenous Leukemia, AML	HMGCLL1					-	Samsung Medical Center
	Breast cancer	TRIB2					-	Genesen Co, Ltd.
	Colorectal cancer	USP21					-	K-MEDI hub
	Solid Tumor	TRIM29					SB24011	SPARK Biopharma
	AML	PIM Kinase					JPC-089	Jeil Pharmaceutical Co., Ltd.

DRUG CLASS	INDICATION	TARGETS	KDDF FUNDING STAGE				PRODUCT CODE	COMPANY
			Discovery	Pre	Ph1	Ph2		
Small mole.	KRAS-mutated solid cancer (Pancreatic, Lung, Colon cancer)	SOS1					-	Jeil Pharmaceutical Co., Ltd.
	Resistant cancer	PIN1					PMB212	PimedBio
	Malignant tumor	EZH1/2					HM97662	Hanmi Pharm. Co., Ltd.
	TNBC	ENPP1					KH0017	KIST
	Solid Tumor	STING					-	KIST
	Solid Tumor	G9a					-	Asan Medical Center
	Breast cancer	MASTL					-	KIRAMS ¹⁷⁾
	Colorectal cancer, Lung cancer, Pancreatic cancer	ULK1					-	TXINNO Bioscience Inc
	Colorectal cancer	ENPP1					TXN10128	TXINNO Bioscience Inc
	Solid tumor	ENPP1					TXN10128	TXINNO Bioscience Inc
	NSCLC, Colorectal cancer, Head and neck cancer	SHP2					KNP-503	KANAPH Therapeutics
	Colorectal cancer (KRAS mutation)	KRAS					-	Zymedi
	TNBC	STAT3					JW2286	JW Pharmaceutical
	Advanced Solid Tumor	AhR					DA-4505	DONG-A ST
	Malignant tumor	FOXN1					KUMC-08-0022, 0055	Korea University
	Colorectal cancer	GCN2					1STBIO-GCN2-01, 1STBIO-GCN2-02, 1STBIO-GCN2-03	1st Biotherapeutics, Inc
	Ovarian cancer, Endometrial cancer, Renal cell carcinoma	HPK1					-	1st Biotherapeutics, Inc
	Brain cancer, Lung cancer	HPK1/MLK3					KHK-1, KHK-2	MD Biopharm
	Prostate cancer	PIP5K1 α					T1522	TSD Life Sciences
	Multiple Myeloma	19S RP UCHL5					-	KRIBB
	Liver cancer, MASH	FLT3/VEGFR2/ PDGFRb TK					MBP-11901	Etnova Therapeutics
	Glioblastoma	SCAP:SREBP1					MFC0101-7043	MEDIFIC
	Glioblastoma	PRMT5					SKL27969	SK Biopharmaceuticals

DRUG CLASS	INDICATION	TARGETS	KDDF FUNDING STAGE				PRODUCT CODE	COMPANY
			Discovery	Pre	Ph1	Ph2		
Small mole.	Solid Tumor	TGFβR1					TU2218	Tium BIO
	Polycythemia vera	HRI					-	NexThera
	NSCLC	EGFR					-	Inno.N
	Pancreatic cancer	SIRT6					SCB0020160	SC-Bio
	Colorectal cancer	mutant RON					WM-S1-030	Wellmarkerbio
	Solid Cancer	TLS					-	D5 Therapeutics
	TNBC	TOP1					PBX-7 series	PINOTBIO
	TNBC	-					AbClick Pro linker	AbTis
	Solid Cancer	PD-1/PD-L1					IA-05370, IA-05386	ILAb
	Castration-resistant prostate cancer	Androgen receptor					ICX-301	Incurix
	Cancer	Myc					ICX-130	Incurix
	AML	STAT3/5					SF-4044	C&C Research Laboratories
	Metastatic Castration Resistant Prostate Cancer	XBP1s					XP-1245	C&C Research Laboratories
	NSCLC, Melanoma	SMARCA2/4					HD-10601	Hyundai Pharm
	NUT Midline Carcinoma	BRD4-NUT					ICT-905 / ICT-1410	InnoCure Therapeutics
	Solid tumor, NSCLC	c-MET					ABN401	ABION
	Incurable cancer	SLC1A5_var					-	Yonsei University
	Glioblastoma, Liver cancer	WNK3					CX003-0023	Checkmate Therapeutics
	KRAS G12X-mutant cancer	DDR1					-	Cureverse
	Cancers (NSCLC, melanoma)with high tumor mutational burden	CSF1R, PI3K δ					MKPD	ChungAng University
	Lung cancer, Solid cancer	CMTM6					-	Kangwon University
	Cancer (BRCA Mutant)	USP1					-	AIGEN Sciences
	Colorectal cancer	CD39					SCB0010336	SC-Bio
	Solid tumor(ovarian, colorectal, melanoma, etc.)	-					-	Samjin Pharmaceutical
	Lung cancer, Colon cancer	APE1					-	KAIST
	Solid cancer	PARP-1					DM-5167	DigmBio Inc.

Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
TPD								
Mole.glue	SCLC, AML	GSPT1					CYRS1542	Cyrus Therapeutics
	Solid tumor (NSCLC, Melanoma, TNBC)	IKZF2					KMG-1694	KRICT
	ACC,CRC	CK1α					PIN-G20	Pin Therapeutics
	MSI-H/dMMR Colon Cancer	CBL-B					-	Immuse Therapeutics
Other-TPD	Castration-resistant prostate cancer	Androgen receptor					-	KRICT
	Breast cancer (ER-positive)	ER					ER-ATTEC	KRICT
	Breast Cancer	3-kinaseα Chaperone					MBT-053	MagicBullet Therapeutics
PROTAC	NSCLC	EGFR mutation					-	Cyrus Therapeutics
	Pancreatic cancer	NDRG3					-	KRIBB
	NSCLC	PLK1					-	DANDI CURE
	NSCLC(EGFR mutation)	EGFR					J2H-2002	J2H Biotech
	AML	CK1α					-	Pin Therapeutics
	NSCLC	PLK1					-	UPPTHERA
	Cancer	AURKA					-	UPPTHERA
	AML	FLT3					YUH1945	Yonsei University
	Castration-resistant prostate cancer	Androgen receptor					UBX-103335	Ubix Therapeutics ¹⁸⁾
	NSCLC	MET					ICT-1402	InnoCure Therapeutics
Small mole.	Solid Tumor	VRK1					-	KRICT

- **ACC**: Adenoid cystic carcinoma
 - **AML**: Acute Myeloid Leukemia
 - **ccRCC**: clear cell renal cell carcinoma
 - **CLL**: Chronic lymphocytic leukemia
- **CRC**: colorectal cancer
 - **GIST**: Gastrointestinal stromal tumor
 - **NHL**: Non-Hodgkin lymphoma
 - **NSCLC**: Non-small cell lung cancer
- **PC**: Prostate cancer
 - **SCLC**: Small cell lung cancer
 - **TNBC**: Triple-negative breast cancer

Immunology




Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Antibody								
mAb	PNH	C5					IM-101	ImmunAbs
	Autoimmune diseases	C5					IM-101	ImmunAbs
	Multiple sclerosis	CD40					PB-40N	PB Immune Therapeutics
	Pemphigus	CD40					PB101	PB Immune Therapeutics
	Asthma, Atopic dermatitis	TCTP/HRF					-	Ewha Women's University
	Rheumatoid arthritis	WARS1					M102AI	MirimGene
	Atopic dermatitis	CD200R1					-	AimedBio Inc
	Rheumatoid arthritis	sFas L					-	Seoul National University
	Asthma	FcεR1α					FANHIE (IgCw-γεκ)	FatiAbGen
	GvHD	SLAMF1, SLAMF7					-	Sungkyunkwan University
	Rheumatoid arthritis, Multiple sclerosis	PIGF					-	Catholic University
	BsAb	Rheumatoid arthritis, Autoimmune diseases	OX40L, TNF-α					IMB-101
Others-Bio.								
Exosome	IBD	CARD9, TRIM62					-	ILIAS Biologics Inc.
Microbiome	Ulcerative colitis	VIP					LIV001	Liveome
	Rheumatoid arthritis	-					BFD1R	BIFIDO
	GvHD	Regulatory T cells					-	Liveome
Others-Synth.								
Nano particles	Psoriasis, Contact dermatitis	Hyaluronic acid					-	Ajou University
	Ischemia reperfusion injury	ROS					BRIXELLE-INFLA	BILIX

Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
rProtein								
Peptide	Atopic dermatitis	FPR2					NCP112	Novacell Technology Inc.
	Multiple sclerosis	FPR					WKYVMm	Sungkyunkwan University
rProtein	IBD, SLE	IL-2					APB-R4	AprilBio
Fusion Protein	Rheumatoid arthritis	Integrin αvβ3/ Siglec-15					MP2021	MEdPACTO
	Psoriasis, Psoriatic arthritis	IL-17A, IL-17F, TNFα					CR-T1-T4	Curogen Technology
Small mole.								
Small mole.	Psoriasis	CR-E1(PELLINO1)					CR-PSZ	Curogen Technology
	Systemic sclerosis	SOS1/RAS					-	Kyungpook University
	Asthma	IL-33					KB1518	AZCURIS
	Psoriasis, Rheumatoid arthritis	Tyk2					-	CrystalGenomics, Inc.
	Atopic dermatitis	STAT3					AD-1045	C&C Research Laboratories
	Ulcerative colitis	PYGL					BJ-80F	INNOVO Therapeutics
	Ulcerative colitis	15-PGDH					INV-008	INNOVO Therapeutics
	Atopic dermatitis	EGR1					-	Konkuk University ²⁰⁾
	Psoriasis, MASH	NLRP3					-	Ajou University
	Psoriasis	Cannabinoid 1 receptor					-	Ajou University
	IBD, Rheumatoid arthritis, Psoriasis, Ankylosing spondylitis, Idiopathic pulmonary fibrosis, MASH	PKM2					LMT-3833	LMT-3833
	Ulcerative colitis, Crohn's disease	PIN1					-	PimedBio
	Crohn's disease	LRRK2					-	Chung Ang University ²¹⁾
	Osteoarthritis	OSCAR					-	KaiPharm
	Crohn's disease	AhR					PB542	Parenchyma Biotech
	Systemic sclerosis	STAT6					-	Catholic University
	Multiple sclerosis	PKCη					-	Hanyang University
	Multiple sclerosis	S1P1					CV-02	CUREVERSE

DRUG CLASS	INDICATION	TARGETS	KDDF FUNDING STAGE				PRODUCT CODE	COMPANY
			Discovery	Pre	Ph1	Ph2		
Small mole.	Autoimmune diseases	RIPK1					-	BiSiChem
	Atopic dermatitis	TSLP/TSLPR					ATB1606	AmtixBio
	Psoriasis	IRAK1/4					-	Dongwha Pharmaceutical
	Multiple sclerosis	Lipocalin 2 (LCN2)					-	K-MEDI hub
TPD								
PROTAC	SLE	IRAK4					-	Gachon University

- GvHD: Graft-versus-host disease
 - IBD: Inflammatory disease
- MS: Multiple sclerosis
 - PNH: Paroxysmal nocturnal hemoglobinuria
- RA: Rheumatoid arthritis
 - SLE: Systemic lupus erythematosus

Metabolic




Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Antibody								
mAb	MASH	Resistin, CAP1					-	Seoul National University Hospital
CGT & Nucleic acids								
GT-Virus vec.	MASH	CR-P1					CR-G001	Curogen Technology
Other-GT	Obesity	FABP4, FABP5					-	Hanyang University
RNA tx.	Sarcopenia	Atrogin-1					AVTM201	AVENTI Inc.
	Obesity, Type 2 Diabetes	FABP4/5					sh(FABP4/5)/ATS9R	Cursus Bio Inc.
Others-Bio.								
Mircrobiome	Obesity	Bacteroides vulgatus, Roseburia intestinalis, Akkermansia muciniphila					KBL981, KBL982, KBL983	Ko Biolabs
rProtein								
Fusion Protein	MASH	TLR5					MSP-306	MediSpan
	Obesity	GDF15					YH34160	Yuhan
	Obesity, Type 2 Diabetes	GLP-1, GLP-2 receptor					PG-102	ProGen. Co.
Peptide	Sarcopenia	TLQP21					-	Asan Medical Center
	MASH	CXCR7					-	Yonsei University
rProtein	Acromegaly	hGH receptor					ALT-B5	Alteogen Inc.
	MASH	FGF21, GLP-1, GCG, α -cytokine					OGB21502	Onegene Biotechnology
	Congenital hyperinsulinism	glucagon					HM15136	Hanmi Pharm. Co., Ltd.
	Sarcopenia	CLCF1					-	KRIBB ²²⁾
	Sarcopenia	NOTCH1					NB-101	NUON Bio

Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Small mole.								
Small mole.	MASH	Serpin Family					DWP220	Daewoong pharmaceutical
	Type 2 Diabetes	PAK4					ND201651	Jeonbuk National University
	MASH	USP1					WUXI1	Yonsei University Health System
	Diabetes	SGLT1/2					JP-2266	Jeil Pharmaceutical Co., Ltd.
	Diabetes, Obesity	Atypical PKC					-	Yonsei University
	MASH	MLKL					-	Hanyang University
	Cirrhosis	SMS1					-	Seoul National University
	Obesity	A2AAR, A3AR					-	Seoul National University ²³⁾
	Sarcopenia	PROKR1 agonist					SP73C-series	Seoul National University
	Diabetes	PPAR γ , AMPA					-	Seoul National University Hospital ²⁴⁾
	Obesity	IP6K					-	KAIST
	Diabetes, Obesity	PPAR γ S273					-	KRIBB
	MASH	TFEB					MSL-7	LysoTech
	Diabetes	CB1R					-	Sungkyunkwan University
	Duchenne muscular dystrophy	NMD					-	RiboTech
	Liver fibrosis	LPAR1					AMS-III-1086	AM Sciences
	MASH	STK25					KSTK-01092	KRICT
	MASH	KARS1					-	Zymedi
	MASH	HTR2A					GM-60106	JD Bioscience
	Bladder disease	BKCa					-	GIST
	Obesity	ALK7					-	Gachon University Gil Medical Center
	Liver fibrosis	DYRK1B					KS-40070	TheraSid Bioscience

• MASH: Metabolic dysfunction-associated steatohepatitis


• T2D: Type 2 diabetes



Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Antibody								
mAb	Myasthenia gravis	Acetylcholine receptor					-	Medytox
CGT & Nucleic acids								
ASO	FCDII Refractory epilepsy	eIF4E					SVG102_N075, SVG102_N182	SoVarGen Co., Ltd.
	Amyotrophic lateral sclerosis	STMN2					-	OliPass Corporation
	Parkinson's disease	TLR2					-	SEASUN Therapeutics, Inc.
GT-Virus vec.	Rett syndrome	MeCP2					-	Rznomics Inc.
	Neuropathic pain	GCH1					AAV-h/r-shGCH1	Yonsei University
	Charcot-Marie-Tooth disease type 1A	PMP22					TGT-001	ToolGen, Inc.
	Spinal cord injury	hLHX3:T2A: hGSTA4					LYH-001	Stand Up Therapeutics
	Huntington's disease	HTT gene (CAG-repeat)					-	GenKOre
	Amyotrophic lateral sclerosis	n/d					C0301	HELIXMITH
RNA tx.	Pediatric epilepsy	MTOR					SVG105	SoVarGen Co., Ltd.
Others-Bio.								
Exosome	Parkinson's disease	Parkin, PGC-1 α					-	Sungkyunkwan University
Others-Synth.								
Nano particles	Cerebral infarction	ROS					CX301	CENYX Biotech
rProtein								
Peptide	Chronic pain	TRPV1					-	Gachon University
	Amyotrophic lateral sclerosis	Zn2+					ZC 301,325,311	Zincure

Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Small mole.								
Small mole.	Parkinson's disease	PON2		HSG4112	Glaceum, Inc.			
	Hearing loss	DRAK1, ADCK4, CDC42BPA		KPLO-2004	Kyungpook University			
	Genetic hearing Loss	KV7.4		B2961, DWP215130	Yonsei University			
	Progressive supranuclear palsy, 4R tauopathies	4R TAU oligomer		DTC0148	KIST			
	Parkinson's disease	LRRK2		-	Whan Inn Pharm. Co., Ltd.			
	Major depressive disorder	A2 adrenergic, NDRI		-	Kyung Hee University			
	Parkinson's disease	α -synuclein		-	Hanyang University			
	Parkinson's disease	ASK1		-	KRICT ²⁵⁾			
	Parkinson's disease	TAS2R		DM3159	DIGMBIO			
	Amyotrophic lateral sclerosis	SOD1		PRG-A-04	PRG S&Tech			
	Neurofibromatosis type 2	TGF- β R1 R255		PRG-N-01	PRG S&Tech			
	Parkinson's disease	PIP5K γ		-	K-MEDI hub			
	Parkinson's disease	c-Abl/LRRK2		FB418	1st Biotherapeutics, Inc			
Parkinson's disease	ERR γ		SKE154	CHA University				
TPD								
Mole.glue	Parkinson's disease	Neuroinflammation		-	AevisBio			
Other_TPD	Parkinson's disease	a-Syn		-	AUTOTAC Bio Inc.			
	Parkinson's disease	α -synuclein		-	Prazer Therapeutics			

Ophthalmology




Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Antibody								
mAb	Degenerative retinal disease	PROX1					-	Celliaz Co.
	Macular degeneration	C5					-	ImmunAbs
	wAMD/DR	Ang2-targeting Tie2 receptor					NTB-101	NEORTES BIO
	Macular degeneration	TIE-2					PMC-403	PharmAbcine Inc
BsAb	wAMD	Tie2, VEGF, Ang-2					-	MabTics
CGT & Nucleic acids								
ASO	Avellino corneal dystrophy	Human TGFβR124H					MDC-101	MediciBio
GT-Virus vec.	Leber congenital amaurosis	CEP290					-	Seoul National University
	Genetic retinal disease	PDE6B					-	Asan Medical Center
	Macular degeneration	sVGFβR1					CRG-02	CdmoGen
	Autosomal dominant Retinitis pigmentosa (adRP)	P23H					RZ-004	Rznomics Inc.
	Retinitis pigmentosa	EYS c.4957dupA					-	Sungkyunkwan University
	Retinitis pigmentosa	RPGR					-	ENCell
	Retinitis pigmentosa	IMPDH1					-	UNIST
	Leber's congenital amaurosis 10	CEP290					GKG001	GenKOre
	Dry-AMD, Inherited retinal disease	Nkx3.2					ICM-322	ICM Co.
RNA tx.	Retinitis pigmentosa	ROR β					-	Olix Pharmaceuticals
Others-Synth.								
Other-S	Macular degeneration	PKC α , Wnt, β -catenin					CGK012	Arez
rProtein								
rProtein	Dry eye disease	HAPLN1					HS-601	HAPLN Science
	Dry-AMD(AMD)	-					-	ILIAS Biologics

DRUG CLASS	INDICATION	TARGETS	KDDF FUNDING STAGE				PRODUCT CODE	COMPANY
			Discovery	Pre	Ph1	Ph2		
Small mole.								
Small mole.	AMD	PDK4					-	Kyungpook University
	Diabetic retinopathy	TGase2					-	K-MEDI hub
	Diabetic retinopathy	TRAP1					-	SMARTIN BIO Inc.
	Diabetic retinopathy	SGLT2					Enavogliflozin	Daewoong Therapeutics Inc.
	Glaucoma, Ocular hypertension	A3AR					FM101	Future Medicine Co., Ltd.
	Dry Macular degeneration	Autophagy					JS-017	VasThera
	Retinal vein occlusion	Co, Fe					-	UNIST
	Dry-AMD	RIPK1					MTS-001	Mother's Pharmaceutical
	Leber hereditary optic neuropathy	NQO1					CR-series	CUROME BIOSCIENCES
	wAMD	-					-	Gachon University
	AMD	BRD2					BBC1501	BenoBio Co.

• (wet/dry)AMD : Age-related macular degeneration

Respiratory



Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Antibody								
mAb	Pulmonary emphysema	Robo1					-	Asan Medical Center
	Pulmonary fibrosis	GM-CSF					-	FNCT Biotech
	idiopathic pulmonary fibrosis	CSF3					FB-101 (CSA1241)	FNCT Biotech
Others-Bio.								
Exosome	Bronchopulmonary Dysplasia(BPD)	Ago2					-	Samsung Medical Center
rProtein								
Peptide	Idiopathic pulmonary fibrosis	Integrin $\alpha V \beta$ -3,5,6					NPT-0025	NEXEL
Small mole.								
Small mole.	Pneumonia	Foxj1					-	Chonnam National University
	COPD	BLT2					LMT-1013	Korea University
	Idiopathic pulmonary fibrosis	CHIT1					INV-005	INNOVO Therapeutics
	Idiopathic pulmonary fibrosis	ALK5					AA2-077	Autotelic Bio
	Idiopathic pulmonary fibrosis	HMGB1					sb1703	SPARK Biopharma
	Idiopathic pulmonary fibrosis	Prolyl-tRNA synthetase (PRS)					DWN12088	Daewoong Pharmaceutical Co., Ltd. ²⁶⁾
	Idiopathic pulmonary fibrosis	Autotacxin					BBT-877	Bridge Biotherapeutics, Inc
	Idiopathic pulmonary fibrosis	ARPC2					-	Sapiensbio
	Asthma	IL-33					AL 5628	AZCURIS

• COPD: Chronic obstructive pulmonary disease

Cardiovascular



Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Antibody								
mAb	Pulmonary hypertension	KARS1					ZMA001	Zymedi
CGT & Nucleic acids								
ASO	Acute heart failure	miRNA (miR-A, 128-3p, 34a-5p, B, 203a-3p)					ANT-A/B	RegenInnopharm
	Myocardial infarction	miRNA (miR-145)					RH001	RegenInnopharm
GT-Virus vec.	Pulmonary hypertension	FGF12					-	GluGene Therapeutics
Other-GT	Peripheral arterial disease, Diabetic peripheral neuropathy	HGF					GB107	G&P Bioscience
rProtein								
Peptide	Pulmonary hypertension	PP1					WK7003	NadianBio
Small mole.								
Small mole.	Congestive heart failure, Chronic renal disease	Pendrin					A4948	Yonsei University
	Aortic Stenosis	DPP-4					Evogliptin	REDNVIA
	Pulmonary hypertension	PDGFR					VRN130184	Voronoi, Inc
	Aortic stenosis	TNAP					-	REDNVIA
	Pulmonary arterial hypertension	PRDX					VTB-10	VasThera

Others



Drug Class	Indication	Targets	KDDF Funding Stage				Product Code	Company
			Discovery	Pre	Ph1	Ph2		
Antibody								
ADC	Osteoporosis	Cathepsin K					-	Ewha Women's University
mAb	Hair loss	CXCL12					EPI-005	EpiBiotech
	Acute kidney injury	Tie2					-	MabTics
	Sudden sensorineural hearing loss	FAM19A5					NS101	Neuracle Science
BsAb	Organ failure (Incompatible blood type)	ABO BCR, CD3					-	Seoul National University
CGT & Nucleic acids								
RNA tx.	Androgenetic alopecia	Androgen receptor					OLX72021	Olix Pharmaceuticals
Others-Bio.								
Other-B	Hearing loss	Mitochondria					-	PAEAN Biotechnology
Exosome	Lesch-Nyhan syndrome	HPRT1					-	Mdimune
Mircrobiome	Trimethylaminuria	TMA					BM109	BioMe Inc.
Others-Synth.								
MRIcontrast agent	MRI contrast agent	Gd-ligand					HNP-2006	Hana Pharm Co., Ltd.
	Lymphadenopathy	-					NEMO-103	INVENTERA Pharmaceuticals
	Diagnostic	Gd-ligand					-	PharmGen Science, Inc.
	Diagnostic	Gadolinium					RD1303	PharmGen Science, Inc.
rProtein								
Peptide	Achondroplasia	NPR-B					PND3174	Peptron, Inc.
	Diabetic foot ulcer	pre-let7 miRNA					LPH105	RegenInnopharm
	Wilson disease	Cu2+					ARBM-101	ARBORMED Pharmaceuticals

DRUG CLASS	INDICATION	TARGETS	KDDF FUNDING STAGE				PRODUCT CODE	COMPANY
			Discovery	Pre	Ph1	Ph2		
rProtein	Others	Hyaluronidase					ALT-BB4	Alteogen Inc. ²⁷⁾
	Gout	Uric Acid					PAT101	ProAbTech
	Degenerative arthritis	bmp7					DRT-01	Darnatein
	Haemophilia A, B	Recombinant coagulation factor VIIa					TU7710	Tium BIO
Small mole.								
Small mole.	Dyspepsia	Ghrelin receptor					KARI101, 201	Kyungpook University ²⁸⁾
	Lymphedema	Nrf2					-	RAPPELER
	Cholelithiasis	Gallstone					2-methoxy-6-methylpyridine (MMP)	Surginex
	Androgenetic alopecia	GFRA1					JW0061	JW Pharmaceutical
	Hyperhidrosis	Muscarinic M3					EFL-1101	eFlask
	Progeria syndromes	Progerin PPI					-	PRG S&Tech
	Osteoarthritis	Caspase					INV-1498	INNOVO Therapeutics
	Alopecia areata	S1PR1&4					Vonifimod (NXC736)	NextGen Bioscience
	Sensorineural hearing loss (noise-induced, ototoxic, and hereditary)	Kv7.4					iN2011-K74	iN Therapeutics
TPD								
PROTAC	Osteoarthritis	Tankyrase					-	Seoul National University

LICENSING DEALS

As of December 2024

NO.	COMPANY	PARTNER	INDICATION	TARGET	DRUG CLASS	CONTRACT TYPE	COUNTRY/ REGION	DATE
1	Seoul National University	Pharosgen	Cancer	Doppel	ADC	Patent Assignment	Republic of Korea	2023.11.
2	IntoCell	ADC Therapeutics	Rare cancer	DLL3	ADC	Platform Technology Transfer	Switzerland	2022.12.
3	LigaChem Biosciences	Amgen, Inc.	Solid Tumor	TROP2	ADC	Non-Exclusive License	USA	2022.12.
		JanssenBiotech, Inc.				ExclusivePatent License	USA	2023.12.
4	Korea University	NEX-I	Metastatic malignant melanoma	Oncokine-2	mAb	Patent Assignment	Republic of Korea	2021.12.
5	NEX-I	Ono Pharma	Lung cancer	NSN-001	mAb	Exclusive Patent License	Japan	2024.03.
6	Wellmarkerbio	N/D	Lung cancer	IGSF1	mAb	N/D	EU	2023.09.
7	KRIBB	TS Bio	Blood Cancer	CD5	CAR_ NK	Exclusive Patent License	Republic of Korea	2023.07.
8	Cartexell Inc	HELIXMITH Co.	Ovarian cancer	L1CAM	CAR-T	Exclusive Patent License	Republic of Korea	2023.10.
9	Yonsei University	DaTES Bio	Pancreactic cancer, Liver cancer	TGFb1, HSP27	GT-Virus vec.	Patent Assignment	Republic of Korea	2022.08.
10	Curigin	Chong Kun Dang pharmaceutical Corp.	Bladder cancer, HNC, Pancreatic cancer	mTOR, STAT3	RNA tx.	Exclusive Patent License	Republic of Korea	2024.04.
11	ChungNam National University	Kainos Medicine	Pancreactic cancer, Liver cancer	FAF1	Other-B	Patent Assignment	Republic of Korea	2023.04.
12	Yonsei University	Fortuga Bio	Solid Tumor	DCs	Other-B	Patent Assignment	Republic of Korea	2022.05.
13	KANAPH Therapeutics	DONG-A ST	Solid Tumor	FAP, IL-12	Fusion Protein	Material Technology Agreement	Republic of Korea	2022.12.
14	Cyrus Therapeutics	Yuhan	Solid tumor	KRAS-SOS1 PPI	Small mole.	Exclusive Patent License	Republic of Korea	2024.03.

NO.	COMPANY	PARTNER	INDICATION	TARGET	DRUG CLASS	CONTRACT TYPE	COUNTRY/ REGION	DATE
15	B2SBio Inc.	Voronoi, Inc	Breast cancer	HER2	Small mole.	Patent Assignment	Republic of Korea	2022.11.
16	Voronoi, Inc	Pyramid Biosciences	TNBC, CDK4/6 Inhibitor resistance solid cancer	Mps1	Small mole.	Exclusive License (Excluding Korea)	USA	2021.11.
17	KIRAMS	Oncord Bio, Inc.	Breast cancer	MASTL	Small mole.	Exclusive Patent License	Republic of Korea	2020.01.
18	Ubix Therapeutics	Yuhan	Castration-resistant prostate cancer	androgen receptor	PROTAC	Exclusive Patent License	Republic of Korea	2024.07.
19	IMBilogics	Navigator Medicines	Rheumatoid Arthritis, autoimmune diseases	OX40L, TNF-a	BsAb	Exclusive Patent License	USA	2024.06.
		Huadong PharmaceuticalCo.					China	2024.08.
20	Konkuk University	Agera Biotech	Atopic dermatitis	EGR1	Small mole.	Patent Assignment	Republic of Korea	2024.11.
21	Chung Ang University	Immuse Therapeutics	Crohn's disease	LRRK2	Small mole.	Material Patent Assignment	Republic of Korea	2022.12.
22	KRIBB	Aventi Biotechnology	Sarcopenia	CLCF1	rProtein	Exclusive Patent License	Republic of Korea	2023.08.
23	Seoul National University	Future Medicine Co.	Obesity	A2AAR, A3AR	Small mole.	Patent Assignment	Republic of Korea	2023.11.
24	Seoul National University Hospital	DALIM BIOTECH	Diabetes	PPARγ, AMPA	Small mole.	Exclusive Patent License	Republic of Korea	2023.09.
25	KRICT	Naason Science	Parkinson's disease	ASK1	Small mole.	Exclusive Patent License	Republic of Korea	2023.10.
25	Daewoong Pharmaceutical Co., Ltd.	CS Pharmaceuticals	Idiopathic pulmonary fibrosis	Prolyl-tRNA synthetase (PRS)	Small mole.	Material Technology Agreement	UK	2023.01.
27	Alteogen Inc.	Sandoz AG	Others	Hyaluronidase	rProtein	Material Technology Export	Switzerland	2022.12.
28	Kyungpook University	Amyloid Solution Inc.	Dyspepsia	Ghrelin receptor	Small mole.	Exclusive Patent License	Republic of Korea	2022.12.

KOREA
DRUG
DEVELOPMENT
FUND

Published by	Korea Drug Development Fund
Publication date	January 2025
Address	9F KPX Building, 137 Mapodaero, Mapo-gu, Seoul, 04143, Korea
Tel	+82-2-6379-3050
E-mail	kddf_bd@kddf.org
Website	www.kddf.org/en